CHICAGO, IL—Low-dose coronary alteplase infused early after PCI does not reduce the likelihood of microvascular obstruction (MVO) in ST-segment elevation MI, the T-Time trial suggests. Colin Berry, MD ...

IIIF provides researchers rich metadata and media viewing options for comparison of works across cultural heritage collections. Visit the IIIF page to learn more. Activase is a recombinant ...

Alteplase is the standard agent used in early reperfusion therapy, but alternative thrombolytic agents are needed. The efficacy and safety of reteplase as compared with alteplase in patients with ...

PRAGUE, Czech Republic — A 0.4-mg/kg bolus dose of tenecteplase (TNKase, Genentech) was associated with functional outcomes and safety similar to those seen with the standard of care, alteplase ...

Thrombolytic therapy with alteplase is widely used for symptomatic PVT, but evidence comparing it directly with tenecteplase ...

Switching from alteplase to tenecteplase as the thrombolytic used routinely for acute ischemic stroke is having multiple benefits for one US hospital system. Tenecteplase was developed as a more ...

DALLAS, Feb. 1, 2024 — Compared with the standard clot-busting medication alteplase, the newer clot-buster tenecteplase may offer a safe, effective and simpler way to treat ischemic (clot-caused) ...

LOS ANGELES -- Tenecteplase (TNKase) used off-label as the routine standard for stroke thrombolysis at one Texas stroke network was both feasible and safe, according to the early experience switching ...